Glaucoma is a progressive disease of the optic nerve, caused by high intraocular pressure (IOP); it is one of the leading causes of vision loss in the United States. Glaucoma treatment aims to lower and stabilize IOP. Pharmacotherapy is widely used, and nonpharmacological interventions continue to gain traction in the treatment of the major subtype of the disease, primary open-angle glaucoma (OAG). Although the U.S. glaucoma therapy market is crowded and highly genericized, branded therapies play an important role, particularly in later lines of therapy. Recent-to-market therapies—Alcon’s Rocklatan and AbbVie’s Durysta—have expanded the treatment armamentarium for OAG. Among nonpharmacological approaches, incisional glaucoma surgery, laser trabeculoplasty, and developments in devices for micro / minimally invasive glaucoma surgery (MIGS) offer additional advances to manage OAG patients.
Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.
Markets Covered: United States.
Primary research: Survey of 85 U.S. ophthalmologists and 20 optometrists.
Key drugs covered: Durysta, Vyzulta, Xelpros, Rhopressa, Rocklatan, Combigan, and Simbrinza.
Key companies: Alcon, AbbVie, Sun Ophthalmics, and Bausch + Lomb
Key insights provided